London, New York, 21 September 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), is pleased to note the publication of a new analyst
Tiziana Life Sci PLC (TILS.L) Publication of Research Note
Tiziana Life Sci PLC (TILS.L) Clinical Study with Nasally Administered Foralumab
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.L) Demerger of StemPrintER and Distribution in Specie
Demerger of StemPrintER and Distribution in Specie Proposed capital reduction and notice of General Meeting
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
N4 Pharma PLC (N4P.L) Technology Transfer and Manufacturing Contract
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit
Tiziana Life Sci PLC (TILS.L) Patent Granted for Anti-IL-6/IL-6
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and other pulmonary diseases
Tiziana Life Sci PLC (TILS.L) Patent Granted for Foralumab
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
Dr Adam M Hill, Chief Executive Officer of Oncimmune Holdings (ONC.L) Podcast
Further evidence for the use of the EarlyCDT Lung blood test in lung cancer screening
Tiziana Life Sci PLC (TILS.L) Update on Timings and Corporate Actions – Charting Update
New York/London, 30 July 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and
Sareum Holdings PLC (SAR.L) Research Update
Encouraging Preclinical Results Generated with Sareum’s TYK2/JAK1 Inhibitors in a Disease Model of Lupus
Tiziana Life Sci PLC (TILS.L) Interview on Bloomberg International
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
